Amgen to Acquire Rodeo Therapeutics, Preclinical Program for PF

Amgen to Acquire Rodeo Therapeutics, Preclinical Program for PF

291340

Amgen to Acquire Rodeo Therapeutics, Preclinical Program for PF

Amgen will acquire Rodeo Therapeutics, along with its preclinical program focused on the development of potential therapies for inflammatory and fibrotic diseases like pulmonary fibrosis (PF). “With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and conditions, Amgen is ideally positioned to rapidly advance our program into the clinic,” Thong Q. Le, the president and CEO of Rodeo said in a press release.…

You must be logged in to read/download the full post.